Pulmonary Vascular Disease News

The FDA has granted breakthrough device designation to a therapeutic intravascular ultrasound system for patients with pulmonary artery hypertension, according to a manufacturer press release.

Warfarin and Pradaxa were both safe and effective at preventing recurrent venous thrombotic events in patients with cerebral venous thrombosis, according to findings from a randomized clinical trial published in JAMA Neurology.

Balloon atrial septostomy appears to be safe and is associated with hemodynamic improvements in patients with advanced pulmonary artery hypertension, according to findings published in CHEST.

New data published in JAMA Network Open suggest that a machine learning algorithm may be able to accurately predict a patient’s risk for pulmonary embolism and may help improve use of CT imaging for PE.

Among patients with idiopathic pulmonary fibrosis, the effects of nintedanib plus sildenafil, as compared with nintedanib alone, on quality of life and FVC did not differ significantly between patients with and those without evidence of right heart dysfunction, according to subgroup analyses of the INSTAGE trial.

Pulmonary embolism appears to be rare in patients presenting with syncope to the ED, according to data published in the Journal of the American College of Cardiology.

Healio Pulmonology has you covered. The Editors have compiled a list of the most-popular articles posted on Healio Pulmonology in July.

When compared with riociguat therapy, balloon pulmonary angioplasty was associated with more improvement in some parameters of hemodynamics and exercise tolerance in patients with inoperable chronic thromboembolic pulmonary hypertension, according to a meta-analysis published in Clinical Cardiology.

Placing an inferior vena cava filter in patients within 72 hours of major trauma did not reduce incidence of symptomatic pulmonary embolism or death at 90 days, according to results of a randomized prospective trial published in The New England Journal of Medicine.

Among patients with portopulmonary hypertension, treatment with macitentan, as compared with placebo, was associated with a 35% decrease in pulmonary vascular resistance, according to the PORTICO study published in The Lancet Respiratory Medicine.